AOD9604 Dosing and Reconstitution Protocol

Overview of AOD9604

AOD9604 is a synthetic peptide (amino acids 177-191 of human growth hormone) designed to promote fat breakdown (lipolysis) and inhibit fat formation without affecting blood sugar, insulin, or muscle growth. It is commonly used for weight loss and body composition improvement via subcutaneous injection. Always consult a healthcare professional before use, as individual responses vary based on body weight, metabolism, and health status. AOD9604 is for research/clinical use and not FDA-approved for weight loss.

Dosing Protocols

Dosing is measured in micrograms (mcg) per day, starting low to assess tolerance. Protocols are tailored for experience level and fat loss goals. Administer via subcutaneous injection (30–31 gauge insulin syringe) in the lower abdomen, upper thighs, or upper arms, rotating sites to avoid irritation.

Beginner (First-Time Users or Low Body Fat Goals)

  • Daily Dose: 250–300 mcg
  • Frequency: Once daily, morning on an empty stomach (30–60 minutes before food)
  • Rationale: Allows body adjustment, minimizes side effects, and aligns with clinical trial doses for fat loss.

Intermediate (Experienced Users or Moderate Fat Loss Goals)

  • Daily Dose: 300–500 mcg
  • Frequency: Once daily or split into two doses (e.g., 150–250 mcg morning and afternoon, 6 hours apart)
  • Rationale: Enhances lipolysis for users with 160–200 lbs body weight or ongoing cycles.

Advanced (High-Tolerance Users or Aggressive Fat Reduction)

  • Daily Dose: 500 mcg (up to 1,000 mcg in rare cases, not recommended above 500 mcg without supervision)
  • Frequency: Split into two doses (e.g., 250 mcg morning and late afternoon, 6 hours apart)
  • Rationale: Maximizes fat oxidation for larger body sizes (>200 lbs) or performance contexts; monitor for diminishing returns.

Cycle Lengths

  • Standard Cycle: 8–12 weeks on, 2–4 weeks off to prevent tolerance.
  • Extended/Intensive: Up to 16 weeks on for advanced users, 4–6 weeks off.
  • Monitoring: Reassess every 4 weeks; combine with diet, exercise, and cardio for best results.

Stacking Options

  • Peptides: CJC-1295/Ipamorelin for HGH synergy or BPC-157 for recovery.
  • Supplements: L-Carnitine or non-stimulant fat burners.
  • Avoid: Over-stacking without medical guidance to prevent interactions.

Benefits

  • Accelerates targeted fat loss (especially abdominal/visceral fat) while preserving muscle.
  • Improves lipid profiles and metabolic health without raising IGF-1 levels.
  • Potential joint repair support; results noticeable in 4–6 weeks.

Side Effects

  • Common (Mild): Injection site redness/itching, headache, fatigue, or nausea (resolve quickly).
  • Rare: Sleep disruption (if dosed late) or allergic reactions.
  • Safety Note: Low risk profile, similar to placebo in trials; no impact on glucose or growth factors.

Reconstitution Protocol

AOD9604’s hydrophobic nature can cause cloudiness, clumping, or gelling in standard bacteriostatic water, reducing bioavailability and causing injection issues. Using 0.6% acetic acid (AA) or an AA-BAC blend (0.1–0.6% final AA concentration) improves solubility by protonating residues, preventing aggregation. This protocol targets a 5 mg vial with a 20:80 AA:BAC blend (0.12% final AA) for a clear, stable solution at ~2.5 mg/mL. Adjust for 10 mg vials by doubling volumes.

Materials Needed

  • 5 mg AOD9604 vial (lyophilized)
  • 0.4 mL 0.6% acetic acid (sterile, pre-made or prepared: 6 µL glacial AA per 1 mL sterile water)
  • 1.6 mL bacteriostatic water (0.9% benzyl alcohol)
  • Sterile syringe (1–3 mL, 30–31 gauge for mixing; 1 mL insulin syringe for dosing)
  • Alcohol swabs
  • Gloves

Step-by-Step Reconstitution

  1. Prepare Workspace: Work in a sterile environment. Wash hands, wear gloves, disinfect surfaces, and equilibrate vial and solvents to room temperature (15–30 minutes) to prevent condensation.
  2. Sanitize Vial: Swab vial’s rubber stopper with 70% alcohol for 15 seconds; let dry.
  3. Draw Solvents:
    • Use a sterile syringe.
    • Draw 0.4 mL 0.6% AA, then 1.6 mL BAC water (total 2 mL, 20:80 ratio).
    • Alternatively, for persistent clumping, use 1 mL AA + 1 mL BAC (50:50, ~0.3% final AA).
  4. Add Solvent:
    • Insert needle at a 45° angle into vial stopper.
    • Slowly inject solvent down the inner glass wall over 20–30 seconds, avoiding direct contact with powder to prevent foaming/clumping.
  5. Dissolve Gently:
    • Remove needle, cap vial.
    • Swirl gently (tilt/roll) for 1–2 minutes. Do not shake to avoid gelling.
    • Let sit at room temperature for 15–30 minutes, swirling every 5 minutes. Full dissolution may take 1 hour.
  6. Verify Clarity: Ensure solution is clear and particle-free. If cloudy, see troubleshooting.
  7. Store: Refrigerate at 2–8°C (36–46°F), protected from light, for up to 28 days. Warm to room temperature before injecting to avoid precipitation.

Dosing Examples (2 mL, ~2.5 mg/mL)

  • 250 mcg: 0.1 mL (10 units on a 1 mL insulin syringe)
  • 300 mcg: 0.12 mL (12 units)
  • 500 mcg: 0.2 mL (20 units)

Troubleshooting Clumping/Cloudiness

  • Immediate Clumping/Gelling: Add 0.5 mL more solvent (maintain 20:80 or 50:50 ratio) or warm vial in a 37°C water bath for 5–10 minutes while swirling. Avoid microwaving.
  • Persistent Cloudiness: Switch to 50:50 blend (1 mL AA + 1 mL BAC) or filter through a 0.22 µm sterile syringe filter. Ensure high-quality AA.
  • Still Unresolved: Test a new vial; peptide quality varies. 0.3% AA (50:50) resolves ~90% of solubility issues vs. ~60% with BAC alone.
  • Gelled Solution: Usable if drawn immediately, but aim for clarity to ensure optimal bioavailability.

Storage and Stability

  • Reconstituted: Refrigerate at 2–8°C for up to 28 days. Discard if cloudy or odorous.
  • Unreconstituted: Freeze at -20°C; avoid freeze-thaw cycles.
  • Injection Prep: Warm to room temperature before drawing to prevent precipitation in syringe.

Notes

  • Start with 20:80 AA:BAC (0.4 mL AA + 1.6 mL BAC for 2 mL) for injection comfort. Use 50:50 (1 mL AA + 1 mL BAC) if clumping persists.
  • Use precise measurements (micropipette or calibrated syringe for AA).
  • Consult a healthcare provider to confirm compatibility with your health profile and peptide source.
  • For 3 mL total solvent (~1.67 mg/mL), use 0.6 mL AA + 2.4 mL BAC (20:80) or 1.5 mL AA + 1.5 mL BAC (50:50).